drugset / Trial / NCT07053332
A Study on Immunotherapy Combined With Radiotherapy for Esophagogastric Junction/Gastric Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
A single-arm, prospective phase II clinical study of neoadjuvant PD-1/CTLA-4 combination antibody with low-dose radiotherapy in resectable dMMR/MSI-H esophagogastric junction/gastric adenocarcinoma.
Timeline
- Start
- 2025-07
- Primary completion
- 2027-12
- Completion
- 2029-08-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iparomlimab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Tuvonralimab | Monoclonal antibody | 5 mg/kg | Intravenous |